Page last updated: 2024-12-05

sulfinpyrazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfinpyrazone is a non-steroidal anti-inflammatory drug (NSAID) that is primarily used to treat gout and hyperuricemia. It is thought to work by inhibiting the production of uric acid, a waste product that can accumulate in the joints and cause inflammation. Sulfinpyrazone is also sometimes used to prevent blood clots in people who have had a heart attack or stroke. The synthesis of sulfinpyrazone involves a multi-step process starting from readily available chemicals. Sulfinpyrazone's effects on the body include reducing uric acid levels, anti-inflammatory properties, and antiplatelet activity. The importance of sulfinpyrazone lies in its ability to manage gout and hyperuricemia, conditions that can cause significant pain and discomfort. Studies on sulfinpyrazone aim to explore its potential in treating other inflammatory conditions, its long-term effects, and its interactions with other medications.'

Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5342
CHEBI ID9342
SCHEMBL ID34421
MeSH IDM0020776

Synonyms (183)

Synonym
sulfinpyrazone (spz)
AC-13602
BIDD:PXR0096
1,2-diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione
CHEBI:9342 ,
1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
1,2-diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine
4-(2-benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione
BRD-A36217750-001-05-6
(+/-)-sulfinpyrazone
DIVK1C_000090
KBIO1_000090
SPECTRUM_001022
IDI1_000090
sulfoxyphenylpyrazolidin
anturano
sulfinpyrazonum [inn-latin]
einecs 200-357-4
g 28,315
sulfinpirazona [inn-spanish]
4-(phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione
hsdb 3396
1,2-diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [german]
nsc 75925
1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione
brn 0713597
PRESTWICK_455
NCGC00016255-01
cas-57-96-5
nsc75925
3,5-pyrazolidinedione, 1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)-
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenyl-pyrazolidine-3,5-dione
anturan
enturan
anturanil
usaf ge-13
enturen
wln: t5vnnv ehj br& cr& e2so&r
sulfinpyrazine
diphenylpyrazone
4-(phenylsulfoxyethyl)-1,5-pyrazolidinedione
nsc-75925
sulfinpyrazon
g 28315
anturidin
sulphinpyrazone
anturane
anturen
3, 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-
PRESTWICK2_000290
BSPBIO_000200
BSPBIO_002040
SPECTRUM5_000984
BPBIO1_000220
PRESTWICK3_000290
AB00052103
sulfinpyrazone
C07317
sulfoxyphenylpyrazolidine
57-96-5
DB01138
MLS001074941
D00449
sulfinpyrazone (jan/usp/inn)
anturane (tn)
NCGC00023932-03
NCGC00023932-04
MLS000028565
smr000058991
KBIOSS_001502
KBIO2_006638
KBIO2_001502
KBIO3_001540
KBIOGR_001449
KBIO2_004070
SPBIO_002419
PRESTWICK0_000290
SPECTRUM4_000845
SPECTRUM2_001324
PRESTWICK1_000290
SPBIO_001447
SPECTRUM3_000590
NINDS_000090
SPECTRUM1500554
NCGC00018267-01
apo-sulfinpyrazone
HMS2092K11
HMS500E12
HMS1568J22
HMS1921C09
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
HMS2095J22
HMS3259I06
pharmakon1600-01500554
nsc757332
nsc-757332
dtxcid003618
tox21_110331
dtxsid0023618 ,
HMS2233H11
S4628 ,
CCG-39262
NCGC00016255-05
NCGC00016255-04
NCGC00016255-07
NCGC00016255-02
NCGC00016255-06
NCGC00016255-03
sulfinpyrazone [usp:inn:ban:jan]
v6ofu47k3w ,
sulfinpyrazonum
1,2-diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin
sulfinpirazona
unii-v6ofu47k3w
FT-0603240
AKOS015913283
gtpl5826
HMS3371B22
sufinpyrazone
suphinpyrazone
1,2-di(phenyl)-4-(2-phenylsulfinylethyl)pyrazolidine-3,5-dione
sulfinpyrazone [who-dd]
1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-3,5-pyrazolidinedione
sulfinpyrazone [usp-rs]
sulfinpyrazone [mart.]
sulfinpyrazone [inn]
sulfinpyrazone [orange book]
sulfinpyrazone [mi]
sulfinpyrazone [jan]
sulfinpyrazone [usp impurity]
sulfinpyrazone [vandf]
sulfinpyrazone [ep impurity]
sulfinpyrazone [ep monograph]
NC00539
1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)pyrazolidine-3,5-dione
SCHEMBL34421
tox21_110331_1
NCGC00016255-10
1,2-diphenyl-4-[2-(phenylsulfinyl)-ethyl]-pyrazolidine-3,5-dione
3,5-pyrazolidinedione, 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-
W-105427
AC-32767
(-+)-sulfinpyrazone
AB00052103_13
1,2-diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione
bdbm50237626
g-28315
SR-01000003152-2
sr-01000003152
sulfinpyrazone, united states pharmacopeia (usp) reference standard
mfcd00057279
sulfinpyrazone, european pharmacopoeia (ep) reference standard
sulfinpyrazone for system suitability, european pharmacopoeia (ep) reference standard
(+/-)-sulfinpyrazone, analytical standard
SR-01000003152-4
SBI-0051528.P003
HMS3712J22
DS-6609
BCP05344
Q3790542
Z1557407327
HY-B1271
BRD-A36217750-001-09-8
HMS3885F12
CS-0013052
diphenylpyrazone;g-28315
H10364
EN300-124005
A869550
sulfinpyrazone; 1,2-diphenyl-4-(2-phenylsulphinylethyl)pyrazolidine-3,5-dione;(+/-)-sulfinpyrazone
sulfinpyrazone for system suitability
(invertedexclamationmarka)-sulfinpyrazone
sulfinpyrazone (ep monograph)
sulfinpyrazonum (inn-latin)
m04ab02
sulfinpyrazone (usp impurity)
sulfinpyrazone (usp-rs)
sulfinpyrazone (ep impurity)
sulfinpyrazone (usp:inn:ban:jan)
sulfinpirazone
sulfinpirazona (inn-spanish)
sulfinpyrazone (mart.)
U0114

Research Excerpts

Overview

Sulfinpyrazone, which is an inhibitor of platelet aggregation, was found to protect animals from these adrenochrome effects.

ExcerptReferenceRelevance
"Sulfinpyrazone, which is an inhibitor of platelet aggregation, was found to protect animals from these adrenochrome effects."( Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias.
Beamish, RE; Dhalla, NS; Dhillon, KS; Singal, PK, 1981
)
1.3

Effects

Sulfinpyrazone has been shown to reduce the arrhythmogenic action of adrenochrome in vivo. It has also been studied extensively as a platelet inhibitor and antithrombotic agent.

ExcerptReferenceRelevance
"Sulfinpyrazone, which has been shown to reduce the arrhythmogenic action of adrenochrome in vivo, significantly reduced the coronary pressure increases."( Adrenochrome-induced coronary artery constriction in the rat heart.
Beamish, RE; Dhalla, NS; Fliegel, L; Karmazyn, M, 1981
)
0.98
"Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent. "( Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Margulies, EH; Sherry, S; White, AM, 1980
)
3.15
"Sulfinpyrazone kinetics has been investigated after intravenous and oral doses. "( Sulfinpyrazone kinetics after intravenous and oral administration.
Humbert, G; Lecaillon, JB; Massias, P; Schoeller, JP; Souppart, C, 1979
)
3.15
"and sulfinpyrazone have been tested in several large scale clinical trials."( [Antiplatelet drugs (author's transl)].
Dechavanne, M; Follea, G; Trzeciak, MC, 1979
)
0.74

Actions

ExcerptReferenceRelevance
"Sulfinpyrazone can cause reversible acute renal failure from acute tubular necrosis in patients with volume depletion."( Acute renal failure due to sulfinpyrazone.
Goral, S; Stone, W; Walls, M, 1998
)
1.32

Treatment

Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II) reduces cardiac mortality and incidence of sudden death. Treatment did not affect the hypoprothrombinemia produced by phenprocoumon nor did it significantly alter the plasma elimination kinetics of the individual (R)- and (S)-enantiomers.

ExcerptReferenceRelevance
"The sulfinpyrazone treatment subsample presented normalized PPT accompanied by reduction of VIII:RAg but not of beta-TG or PF4 levels."( In vivo platelet hyperactivity and factor VIII related antigen increase long after myocardial infarction. A controlled effect of sulfinpyrazone.
Beggi, P; Boschetti, C; Cortellaro, M; Polli, EE, 1981
)
0.95
"In a sulfinpyrazone-treated group 3 out of 8, and in a metoprolol-treated group 2 out of 5 animals died."( Sudden death related to advanced coronary atherosclerosis in mini-pigs: influence of some drugs.
Jacobsson, L; Lundholm, L; Wingren, G, 1984
)
0.72
"Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II), starting 25--35 days after the acute myocardial infarction, reduces cardiac mortality and incidence of sudden death for a period of two years."( [Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Oelz, O, 1979
)
0.98
"Sulfinpyrazone treatment did not affect the hypoprothrombinemia produced by phenprocoumon nor did it significantly alter the plasma elimination kinetics of the individual (R)- and (S)-enantiomers."( The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
Gibaldi, M; Goulart, DA; Heimark, LD; O'Reilly, RA; Toon, S; Trager, WF, 1987
)
1.35
"Treatment with sulfinpyrazone and 5-nitrouracil (both inhibitors of UGT enzymes) significantly increased the toxicity of chlorantraniliprole against the third instar larvae of P. "( Over-expression of UDP-glycosyltransferase gene UGT2B17 is involved in chlorantraniliprole resistance in Plutella xylostella (L.).
Gao, X; Li, X; Liang, P; Zhu, B, 2017
)
0.81
"Pretreatment with sulfinpyrazone at 100 mg kg-1 i.v."( Effect of prostaglandin synthesis inhibition and sympathectomy on ouabain-induced arrhythmia in cats.
Jurkiewicz, N; Kelliher, GJ; Soifer, BE,
)
0.45
"Treatment with sulfinpyrazone or aspirin/dipyridamole did not produce changes in platelet survival time or plasma beta TG concentration that were significantly different from the values during the placebo phase."( Platelet tests and antiplatelet drugs in coronary artery disease.
Butt, R; de Boer, AC; Gent, M; Genton, E; Han, P; Turpie, AG, 1983
)
0.61
"Treatment with sulfinpyrazone (800 mg/day) was started 24 hours after operation in 130 patients; 125 patients received placebo."( Effects of sulfinpyrazone on early graft closure after myocardial revascularization.
Baur, HR; Gobel, FL; Pierach, CA; VanTassel, RA, 1982
)
0.99
"Pretreatment with sulfinpyrazone reduced isoproterenol-induced lesions by 42%."( Reduction in the severity of myocardial infarction by sulfinpyrazone.
Innes, IR; Weisman, H, 1981
)
0.83
"Treatment of sulfinpyrazone-induced acute tubular necrosis consists of intravascular hydration, supportive care, and withholding sulfinpyrazone."( Acute renal failure due to sulfinpyrazone.
Goral, S; Stone, W; Walls, M, 1998
)
0.95

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"The available scientific data indicate that the pathomechanism of Parkinson's disease (PD) involves the accumulation of endogenous and exogenous toxic substances."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.39
" The explanation of these findings would be that the stimulation of MRP1- and MRP2-mediated transport of glutathione conjugates of toxic substances may have slight beneficial effects, while stimulation of MRP4-mediated efflux of brain urate, which has an important antioxidant potency, may worsen the effects of oxidative stress."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" In vivo much of the activity is probably due to the thioether or sulphide metabolite which has a greater potency and a longer half-life than the parent compound."( Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.
Angus, R; George, CF; Howarth, P; Oates, J; Renwick, AG; Sembi, J; Strong, HA,
)
0.13
" Chronic treatment with sulphinpyrazone reduced the plasma AUC of the sulfide and caused a decrease in its elimination half-life (20."( Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.
de Vries, J; Gundert-Remy, U; Harenberg, J; Hildebrandt, R; Schlicht, F; Staiger, C; Wang, NS; Weber, E, 1985
)
0.27
" It is important in pharmacokinetic studies to measure plasma levels of both acetylsalicylic acid and salicylic acid."( Determinants of the pharmacokinetics of antithrombotic drugs.
Marks, GS, 1983
)
0.27
" Sulphinpyrazone was rapidly absorbed and eliminated with a half-life of approximately 4 h irrespective of dose."( Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.
Bradbrook, ID; John, VA; Morrison, PJ; Rogers, HJ; Spector, RG, 1982
)
0.26
" Pharmacokinetic parameters of nateglinide were determined following the administration of nateglinide alone, and when administered in combination with sulfinpyrazone."( Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
Ligueros-Saylan, M; McLeod, J; Prasad, P; Sabia, H; Smith, H; Sunkara, G; Wang, Y, 2004
)
0.52
" The time to reach Cmax (tmax) and the elimination half-life of nateglinide were similar between the two treatments."( Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
Ligueros-Saylan, M; McLeod, J; Prasad, P; Sabia, H; Smith, H; Sunkara, G; Wang, Y, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"Only drug-drug interactions that are believed clinically important and that are primarily pharmacokinetic in nature are discussed in this article."( Therapeutic implications of drug interactions with acetaminophen and aspirin.
Hayes, AH, 1981
)
0.26
" Drug-drug interactions (DDIs) caused by induction of CYP3A4 can result in decreased exposure to coadministered drugs, with potential loss of efficacy."( Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
de Morais, SM; Fahmi, OA; Liras, JL; Maurer, TS; Mills, JB; Ripp, SL; Trevena, KA, 2006
)
0.33

Bioavailability

ExcerptReferenceRelevance
" Intravenous administration of sulfinpyrazone demonstrated that the tablets had a high bioavailability (about 90%), and the time to peak plasma concentration of the sulfide and the amount formed were similar to those seen after oral administration."( Role of the gut flora in the reduction of sulfinpyrazone in humans.
George, CF; Oates, J; Renwick, AG; Sembi, J; Strong, HA, 1984
)
0.82
" administration of sulphinpyrazone (10 mg/kg) to rabbits showed that the oral route was associated with an incomplete bioavailability and a six-fold greater formation of the active sulphide metabolite."( The site of reduction of sulphinpyrazone in the rabbit.
George, CF; Renwick, AG; Strong, HA, 1984
)
0.27
" Oral administration was associated with a bioavailability of about 75% and with a 3-fold greater formation of the sulphide."( The role of the gut flora in the reduction of sulphinpyrazone in the rat.
Cumberland, J; Evans, SP; George, CF; Renwick, AG; Sweatman, TW, 1982
)
0.26
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The dosage of sulfinpyrazone used in this trial was well tolerated by all patients and no side effects were observed. Concomitant sulfin pyrazone dosing markedly increased hypoprothrombinemia, decreased clearance of (S)-warfarin, and increased clearance of(R) warfarin.

ExcerptRelevanceReference
" Maintenance therapy with the same dosage is also recommended."( [Antiplatelet therapy in cardiac diseases].
Aosaki, M; Hosoda, S; Iwade, K; Kimata, S, 1992
)
0.28
"273 patients suffering from ischemic heart disease were treated with Anturan for one year at a daily dosage of 800 mg."( Anturan for secondary prophylaxis of myocardial infarction.
Bokarev, IN; Golikov, AP; Lusov, VA; Ptushkin, VV; Savenkov, MP; Seregina, MV; Zvereva, TV, 1988
)
0.27
" None of the drugs inhibited chemotaxis in a dose-response fashion at concentrations achievable in human plasma."( Search for drugs that may reduce the load of neutrophil azurophilic granule enzymes in the lungs of patients with emphysema.
Cohen, AB; Miller, EJ; Stevens, MD, 1989
)
0.28
"Theobromine metabolism and clearance were investigated at steady-state under chronic oral dosing conditions in eight healthy volunteers, four of whom were cigarette smokers."( Influence of cimetidine, sulfinpyrazone, and cigarette smoking on theobromine metabolism in man.
Attwood, J; Birkett, DJ; Miners, JO; Wing, LM,
)
0.43
" However, twice daily dosing with dazoxiben was effective."( Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
Ambler, J; Butler, KD; Butler, PA; Shand, RA; Wallis, RB, 1987
)
0.27
" This was associated with increasing inhibition of ex vivo platelet aggregation induced by platelet-activating factor during the dosing period, but inhibition of arachidonic acid-induced aggregation did not increase cumulatively during dosing and collagen-induced aggregation was not inhibited."( Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
FitzGerald, GA; Pedersen, AK, 1985
)
0.49
" In addition, because frequent repeated and synchronous dosing of aspirin was necessary, aspirin's potentiating effects appear to be produced by mechanism(s) unrelated to its potent, irreversible inhibition of platelet cyclooxygenase."( Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.
Bjornsson, TD; Hanson, SR; Harker, LA, 1985
)
0.47
" Concomitant sulfinpyrazone dosing markedly increased hypoprothrombinemia, decreased clearance of (S)-warfarin, and increased clearance of (R)-warfarin."( The warfarin-sulfinpyrazone interaction: stereochemical considerations.
Gibaldi, M; Goulart, DA; Low, LK; Motley, CH; O'Reilly, RA; Toon, S; Trager, WF, 1986
)
1.01
" Each patient was allocated, according to his/her baseline values of serum uric acid or serum creatinine to four different sulphinpyrazone incremental dosage schedules."( Sulphinpyrazone dose schedule in hyperuricemic patients with cardiovascular diseases: tolerability assessment.
Bertoli, L; Borghi, C; Busnardo, I; Zagnoni, P, 1985
)
0.27
" Starting dosage was 200 mg per day; daily dosage was then increased every 4 days of 200 mg, or kept constant for another 4 days, according to each patient's renal function, up to 800 mg per day."( [Renal tolerance of an incremental dosage regimen of anturan in the aged with altered renal function]].
Bertolini, G; Borghi, C; Naliato, P, 1985
)
0.27
" The dosage of sulfinpyrazone used in this trial was well tolerated by all patients and no side effects were observed."( [Interaction of sulfinpyrazone (Anturan) and glibenclamide (Euglucon) in type II diabetic patients].
Irsigler, K; Kritz, H; Najemnik, C, 1983
)
0.96
" Starting dosage was 200 mg per day; daily dosage was then increased, every 4 days, by 200 mg or kept constant for another 4 days, according to each patient's basal renal function, up to the maintenance dose: 800 mg/day."( Sulphinpyrazone in cardiovascular elderly azotemic patients: a proposal of a 'guided' incremental dose schedule.
Borghi, C; Dacco', L; Di Ruvo, R; Palummeri, E; Passeri, M, 1984
)
0.27
" Blood was drawn before the study started, 3-4 h after the initial dosage, 12 h after the 10th dosage on the 5th day, and 3-4 h after the 11th (final) dosage on the 6th day."( The effect of sulphinpyrazone on whole blood thromboxane and prostacyclin generation in man.
Badenhorst, PN; Deckmyn, H; Vermylen, J, 1982
)
0.26
" Sulphinpyrazone in both dosage regimens increased uric acid excretion and lowered plasma urate concentration."( Sulphinpyrazone and renal function following myocardial infarction.
Choudhury, SL; Morgan, DB; Swaminathan, R; Taylor, SH; Wieringa, G, 1983
)
0.27
" Dose-response curves for electrophysiological and mechanical effects of sulphinpyrazone were obtained."( Electrophysiological and mechanical effects of sulphinpyrazone on isolated rat atria.
Hotvedt, R; Kristiansen, O; Refsum, H, 1982
)
0.26
" It is concluded that when initiating and withdrawing treatment with SP in a patient receiving AC, the prothrombin time should be checked daily for a few days to adapt (reduce) the dosage of AC to the change in prothrombin time induced by SP."( [The effect of sulfinpyrazone on the coagulation-inhibiting action of acenocoumarol].
Fontanilles, F; Holt, NF; Michot, F, 1981
)
0.62
" The average racemic plasma warfarin concentration over a dosage interval when adjusted for warfarin dose was not altered by sulphinpyrazone administration."( Interaction of sulphinpyrazone with warfarin.
Birkett, DJ; Foenander, T; Gallus, AS; Miners, JO; Wanwimolruk, S, 1982
)
0.26
" In the light of a recently proposed critical balance of vascular antiaggregatory prostacyclin and platelet proaggregatory TXA2 very low dose ASA might offer advantages over conventional dosage of ASA and should be evaluated in thromboembolic disorders."( Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man.
Lorenz, R; Siess, W; Weber, PC, 1981
)
0.49
" Allopurinol is more frequently used than uricosuric agents such as probenecid, and toxicity may be largely avoided by tailoring dosage schedules according to renal function."( Risks and benefits of drugs used in the management and prevention of gout.
Conaghan, PG; Day, RO, 1994
)
0.29
"Following the intraperitoneal administration of silymarin (with MRP1, 2, 4 and 5 inhibitory effects), naringenin (with MRP1, 2 and 4 stimulatory effects), sulfinpyrazone (with MRP1, 4 and 5 inhibitory and MRP2 stimulatory effects) and allopurinol (with MRP4 stimulatory effect in doses of 100 mg/kg, 100 mg/kg, 100 mg/kg and 60 mg/kg, respectively, for one week before and after the administration of MPTP in C57B/6 mice in acute dosing regimen the striatal concentrations of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid has been measured using high-performance liquid chromatography."( Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
uricosuric drugA gout suppressant that acts directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
sulfoxideAn organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
pyrazolidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (60)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency11.57650.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency11.15000.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency11.15000.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.80190.177814.390939.8107AID2147
phosphopantetheinyl transferaseBacillus subtilisPotency14.08790.141337.9142100.0000AID1490; AID2701; AID2707
TDP1 proteinHomo sapiens (human)Potency15.74860.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency2.51190.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency0.89130.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.79430.011212.4002100.0000AID1030
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency44.66846.309627.099079.4328AID602179
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.89020.01237.983543.2770AID1645841
farnesoid X nuclear receptorHomo sapiens (human)Potency37.57510.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency29.84930.005428.02631,258.9301AID1346982
GVesicular stomatitis virusPotency3.09010.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency33.48890.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency7.49720.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.07950.035520.977089.1251AID504332
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency28.18381.000012.232631.6228AID1452
cytochrome P450 2C9 precursorHomo sapiens (human)Potency10.00000.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency14.99220.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency28.18380.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency24.03530.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency17.40030.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency10.00000.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency9.44950.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency31.62280.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency8.28520.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency22.50240.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency9.02010.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency9.44951.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency3.01310.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
fMet-Leu-Phe receptorHomo sapiens (human)IC50 (µMol)14.40005.30009.166714.4000AID519
Bile salt export pumpHomo sapiens (human)IC50 (µMol)11.00000.11007.190310.0000AID1443986
fMet-Leu-Phe receptorHomo sapiens (human)IC50 (µMol)10.00000.02004.006710.0000AID594625
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)509.10000.00021.557410.0000AID261010
Lanosterol 14-alpha demethylaseHomo sapiens (human)IC50 (µMol)200.00000.05001.43904.0000AID322753
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00050.00000.00060.0019AID1618606
Solute carrier family 22 member 12Homo sapiens (human)IC50 (µMol)100.00000.02602.61527.3000AID329663
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (146)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 5Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 5Homo sapiens (human)
purine nucleotide transportMultidrug resistance-associated protein 5Homo sapiens (human)
hyaluronan biosynthetic processMultidrug resistance-associated protein 5Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 5Homo sapiens (human)
heme transmembrane transportMultidrug resistance-associated protein 5Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 5Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 5Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 5Homo sapiens (human)
cGMP transportMultidrug resistance-associated protein 5Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 5Homo sapiens (human)
folate transmembrane transportMultidrug resistance-associated protein 5Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 5Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 5Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
chemotaxisfMet-Leu-Phe receptorHomo sapiens (human)
signal transductionfMet-Leu-Phe receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
nitric oxide mediated signal transductionfMet-Leu-Phe receptorHomo sapiens (human)
complement receptor mediated signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationfMet-Leu-Phe receptorHomo sapiens (human)
inflammatory responsefMet-Leu-Phe receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayfMet-Leu-Phe receptorHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
steroid biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol metabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein catabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein secretionLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of amyloid-beta clearanceLanosterol 14-alpha demethylaseHomo sapiens (human)
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 12Homo sapiens (human)
response to xenobiotic stimulusSolute carrier family 22 member 12Homo sapiens (human)
urate transportSolute carrier family 22 member 12Homo sapiens (human)
cellular homeostasisSolute carrier family 22 member 12Homo sapiens (human)
cellular response to insulin stimulusSolute carrier family 22 member 12Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 12Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 12Homo sapiens (human)
renal urate salt excretionSolute carrier family 22 member 12Homo sapiens (human)
organic anion transportSolute carrier family 22 member 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (67)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
ATP bindingMultidrug resistance-associated protein 5Homo sapiens (human)
organic anion transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
heme transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 5Homo sapiens (human)
macromolecule transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
carbohydrate derivative transmembrane transporter activityMultidrug resistance-associated protein 5Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
G protein-coupled receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
G protein-coupled receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
N-formyl peptide receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
scavenger receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
protein bindingfMet-Leu-Phe receptorHomo sapiens (human)
RAGE receptor bindingfMet-Leu-Phe receptorHomo sapiens (human)
complement receptor activityfMet-Leu-Phe receptorHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
iron ion bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol 14-demethylase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
heme bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenLanosterol 14-alpha demethylaseHomo sapiens (human)
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
urate transmembrane transporter activitySolute carrier family 22 member 12Homo sapiens (human)
PDZ domain bindingSolute carrier family 22 member 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (48)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
Golgi lumenMultidrug resistance-associated protein 5Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 5Homo sapiens (human)
endosome membraneMultidrug resistance-associated protein 5Homo sapiens (human)
membraneMultidrug resistance-associated protein 5Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 5Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 5Homo sapiens (human)
membraneMultidrug resistance-associated protein 5Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmfMet-Leu-Phe receptorHomo sapiens (human)
plasma membranefMet-Leu-Phe receptorHomo sapiens (human)
membranefMet-Leu-Phe receptorHomo sapiens (human)
secretory granule membranefMet-Leu-Phe receptorHomo sapiens (human)
azurophil granule membranefMet-Leu-Phe receptorHomo sapiens (human)
ficolin-1-rich granule membranefMet-Leu-Phe receptorHomo sapiens (human)
plasma membranefMet-Leu-Phe receptorHomo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
endoplasmic reticulum membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneSolute carrier family 22 member 12Homo sapiens (human)
membraneSolute carrier family 22 member 12Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 12Homo sapiens (human)
brush border membraneSolute carrier family 22 member 12Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (178)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1221978Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221973Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID171435The compound was tested ex vivo at a dose of 0.04 mmol/kg for collagen induced platelet aggregation in rat1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID171444The compound was tested ex vivo at a dose of 0.15 mmol/kg for collagen induced platelet aggregation in rat1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID680784TP_TRANSPORTER: transepithelial transport (basal to apical) in MRP2-expressing MDCKII cells2000British journal of cancer, Aug, Volume: 83, Issue:3
Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1070215Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID171439The compound was tested ex vivo at a dose of 0.08 mmol/kg for collagen induced platelet aggregation in rat1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID594625Antagonist activity at FPR12011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Discovery of small molecule human FPR1 receptor antagonists.
AID171437The compound was tested ex vivo at a dose of 0.08 mmol/kg for ADP induced platelet aggregation in rat1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID681103TP_TRANSPORTER: inhibition of Glutathione efflux (Sulfinpyrazone: 3200. uM) in MRP1-expressing MDCKII cells2000British journal of cancer, Aug, Volume: 83, Issue:3
Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export.
AID1221972Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID75908The compound was tested ex vivo at a dose of 0.15 mmol/kg for collagen induced platelet aggregation in rat1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID680597TP_TRANSPORTER: increase in Etoposide intracellular accumulation (Etoposide: 2 uM, Sulfinpyrazone: 2000 uM) in MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse2001The Journal of biological chemistry, Dec-07, Volume: 276, Issue:49
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID171432The compound was tested ex vivo at a dose of 0.04 mmol/kg for ADP induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID106806Inhibition of malate dehydrogenase (MDH) at 400 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID171431The compound was tested ex vivo at a dose of 0.02 mmol/kg for collagen induced platelet aggregation in rat; ND=No data1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID92249The compound was tested ex vivo at a dose of 0.15 mmol/kg for ADP induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID171430The compound was tested ex vivo at a dose of 0.02 mmol/kg for ADP induced platelet aggregation in rat; ND=No data1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID604742Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1221980Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID679227TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, Sulfinpyrazone:30uM) in membrane vesicles from MRP7-expressing HEK293 cells2003Molecular pharmacology, Feb, Volume: 63, Issue:2
Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1221971Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID680694TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in the presence of Sulfinpyrazone at 5mM in LLC-GA5-COL150 cells2004British journal of pharmacology, Dec, Volume: 143, Issue:7
Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
AID1221979Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID321179Inhibition of thrombin-induced platelet aggregation in human blood by turbidimetric method2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID75903The compound was tested ex vivo at a dose of 0.08 mmol/kg for collagen induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID304345Inhibition of thrombin-induced platelet aggregation in human platelets after 5 mins by turbidimetric method2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.
AID261010Inhibition of thrombin-induced platelet aggregation2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID681875TP_TRANSPORTER: inhibition of PMEA efflux (PMEA: 1 uM) in MRP5-expressing MDCKII cells2000Proceedings of the National Academy of Sciences of the United States of America, Jun-20, Volume: 97, Issue:13
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.
AID74612The compound was tested ex vivo at a dose of 0.04 mmol/kg for ADP induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID680100TP_TRANSPORTER: increase in saquinavir intracellular accumulation in the presence of Sulfinpyrazone at 5mM in LLC-GA5-COL150 cells2004British journal of pharmacology, Dec, Volume: 143, Issue:7
Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID74613The compound was tested ex vivo at a dose of 0.04 mmol/kg for collagen induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID604743Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID604744Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID93144The antiplatelet activity was tested by the turbidimetric method in washed human platelets using thrombin as agonist.2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID92228In vitro inhibitory activity against human platelet aggregation in the presence of collagen1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID171433The compound was tested ex vivo at a dose of 0.04 mmol/kg for ADP induced platelet aggregation in rat1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID160102Tested for anti-platelet activity by turbidimetric method using thrombin as agonist in washed platelet2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Pyridazines. Part 28: 5-alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors.
AID329663Inhibition of human URAT1-mediated urate uptake in HEK293 cells2007Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 35, Issue:6
Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells.
AID681909TP_TRANSPORTER: inhibition of MTX uptake (MTX: 20 uM, Sulfinpyrazone: 300 uM) in membrane vesicles from MRP4-expressing Sf9 cells2002Cancer research, Jun-01, Volume: 62, Issue:11
Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID75902The compound was tested ex vivo at a dose of 0.08 mmol/kg for ADP induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID604741Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID322753Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay2007Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID680792TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical)(Vinblastine: 0.035 uM, Sulfinpyrazone: 1000 uM) in MRP2-expressing MDCKII cells2002Pharmacology, , Volume: 64, Issue:3
Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID75904The compound was tested ex vivo at a dose of 0.15 mmol/kg for ADP induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID624647Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID75899The compound was tested ex vivo at a dose of 0.02 mmol/kg for collagen induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID75906The compound was tested ex vivo at a dose of 0.15 mmol/kg for collagen induced platelet aggregation in guinea pig1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1345080Human Urate anion exchanger 1 (Urate transporter)2007Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 35, Issue:6
Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells.
AID1345827Human FPR1 (Formylpeptide receptors)2005Journal of biomolecular screening, Jun, Volume: 10, Issue:4
High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,061)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990917 (86.43)18.7374
1990's55 (5.18)18.2507
2000's47 (4.43)29.6817
2010's31 (2.92)24.3611
2020's11 (1.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.15 (24.57)
Research Supply Index7.17 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index80.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials172 (15.33%)5.53%
Reviews154 (13.73%)6.00%
Case Studies47 (4.19%)4.05%
Observational0 (0.00%)0.25%
Other749 (66.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]